Trial Profile
Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in Pancreatic Cancer Patients Receiving Treatment With Gemcitabine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 May 2019
Price :
$35
*
At a glance
- Drugs PCI 27483 (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Adverse reactions
- Sponsors Pharmacyclics
- 04 Jun 2013 Results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
- 04 Jun 2013 Status changed from active, no longer recruiting to completed.
- 25 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.